Ethosuximide and Pentoxifylline in the Treatment of Abdominal Pain Related to Irritable Bowel Syndrome
Key facts
- Phase
- Phase 3
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Tanta University
- Trial code
- NCT04217733
- Record updated
- 3 January 2020
- Original description
Ethosuximide and pentoxifylline in the treatment of abdominal pain related to irritable bowel syndromeRead full original descriptionShow less
A Comparative Study to Assess Safety and Effectiveness of Ethosuximide and Pentoxifylline in the Treatment of Abdominal Pain Related to Irritable Bowel Syndrome
Ethosuximide and pentoxifylline in the treatment of abdominal pain related to irritable bowel syndrome
Inclusion: • Age ≥ 18 years,; Man and Women, Negative pregnancy test and effective contraception,; IBS defined by the Rome criteria IV; During the previous seven days the inclusion visit, average numeric rating scale (NRS) pain ≥ 4; IBS Treatment stable for 1 month.
Exclusion: • Breastfeeding; Diabetic patients; Significant liver function abnormalities (transaminases> 3N, cholestasis) and moderate renal disease (MDRD <60 ml / min); Addiction to alcohol and / or drugs,; Antiepileptic drugs taken (epilepsy or chronic pain); Chronic pain of greater intensity than that related to IBS,; Known Allergyto succinimides (ethosuximide, methsuximide, phensuximide) and pentoxifylline; History or current severe depression (hospitalization, long-term antidepressant treatment); Psychotic disorders,.